Bon Natural Life
Bon Natural Life's revenue fell 21.7% to $19 million in fiscal 2025. Its operating margin was −8.7%, down from 7.9% a year earlier. Free cash flow was $0 million. The diluted share count rose 2766.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Income statement
From fiscal 2019 to 2024, earnings per share fell 49.4% a year and net income 31.2% a year. Bon Natural Life then lost money in fiscal 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 4 | — | 0 | 0 | 6 |
| Debt incl. finance leases | 3 | 5 | 4 | 7 | 12 |
| Net debt (negative means net cash) | −1 | — | 4 | 7 | 6 |
| Net debt to EBITDA | −0.1x | — | 0.5x | 2.4x | — |
| Debt to equity | 0.1x | 0.2x | 0.1x | 0.2x | 0.2x |
| Interest coverage | 12.9x | 14.8x | 24.9x | 6.2x | −4.4x |
| Current ratio | 2.2x | 2.2x | 2.5x | 2.4x | 1.7x |
| Quick ratio | 2.0x | 1.9x | 2.4x | 2.3x | 1.6x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 1 of 9 | 2 of 9 |
| Rule of 40 | −3.6% | −51.6% | −21.0% |
| Altman Z'' | 7.79 | 6.35 | 4.25 |
| Accruals ratio | 12.4% | 15.0% | −2.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Fail | Fail | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | 3 of 9 | 1 of 9 | 2 of 9 |
Compare
Put Bon Natural Life side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Bon Natural Life | FY25 | −21.7% | −8.7% | 0.7% | −2.2% | — | 2 | |
| Axil Brands | FY26 | 17.5% | 9.7% | −0.3% | — | — | — | Compare |
| United Guardian | FY25 | −13.4% | 21.3% | 18.1% | — | — | — | Compare |
| Bioharvest Sciences | FY25 | 37.0% | −16.2% | −27.8% | — | — | — | Compare |
| Natural Health Trends | FY25 | −7.4% | −4.5% | −15.2% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 16 | 18 | 26 | 30 | 30 | 24 | 19 |
| Revenue growth | — | 11.1% | 39.9% | 17.3% | −1.3% | −19.2% | −21.7% |
| Gross profit | 5 | 5 | 7 | 9 | 9 | 7 | 4 |
| Research and development | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Operating income | 3 | 4 | 5 | 7 | 6 | 2 | −2 |
| Net income | 3 | 3 | 5 | 6 | 5 | 0 | −2 |
| Diluted EPS (US$) | 125.00 | 145.00 | 170.00 | 185.75 | 124.92 | 4.14 | −0.72 |
| Diluted shares (millions) | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Cash flow | |||||||
| Cash from operations | 7 | 3 | 4 | −0 | −1 | −8 | 0 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | 7 | 3 | 4 | −0 | −1 | −8 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | 0 | 0 | 0 | 0 | 1 | 1 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | — | 0 | 4 | — | 0 | 0 | 6 |
| Debt incl. finance leases | — | 5 | 3 | 5 | 4 | 7 | 12 |
| Total assets | — | 25 | 36 | 37 | 47 | 62 | 85 |
| Total liabilities | — | 14 | 10 | 7 | 11 | 17 | 27 |
| Shareholders' equity | 7 | 10 | 26 | 30 | 36 | 44 | 58 |
| Margins and ratios | |||||||
| Gross margin | 32.2% | 28.6% | 27.9% | 31.5% | 29.9% | 29.8% | 20.8% |
| Operating margin | 19.4% | 19.0% | 21.2% | 22.1% | 20.1% | 7.9% | −8.7% |
| Net margin | 15.7% | 16.6% | 18.0% | 20.9% | 15.6% | 1.7% | −10.7% |
| Free cash flow margin | 42.0% | 14.3% | 15.7% | −0.7% | −2.3% | −32.4% | 0.7% |
| Rule of 40 (growth + FCF margin) | — | 25.5% | 55.6% | 16.6% | −3.6% | −51.6% | −21.0% |
| Return on capital | — | — | 22.0% | — | — | 2.1% | −2.2% |
| Return on equity | — | — | 25.1% | 22.4% | 14.1% | 1.0% | −3.9% |
| Return on assets | — | — | 14.9% | 16.9% | 11.0% | 0.7% | −2.7% |
| Net debt to EBITDA | — | 1.3x | −0.1x | — | 0.5x | 2.4x | — |